Related references
Note: Only part of the references are listed.Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor-or intermediate-risk cytogenetics
Jiri Mayer et al.
BMC CANCER (2014)
Safety and clinical activity of 5-aza-2′-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia
Christopher B. Benton et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass et al.
NATURE (2014)
Treatment of early gastric cancer in the Western World
Elfriede Bollschweiler et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Decitabine reactivated pathways in platinum resistant ovarian cancer
Fang Fang et al.
ONCOTARGET (2014)
Identification of genes specifically methylated in Epstein-Barr virus-associated gastric carcinomas
Toshiyuki Okada et al.
CANCER SCIENCE (2013)
Epstein-Barr virus presence in pediatric diffuse large B-cell lymphoma reveals a particular association and latency patterns: Analysis of viral role in tumor microenvironment
Melina Cohen et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Role of DNA methylation in the development of Epstein-Barr virus-associated gastric carcinoma
Mari Saito et al.
JOURNAL OF MEDICAL VIROLOGY (2013)
Epstein-Barr Virus Infection as an Epigenetic Driver of Tumorigenesis
Atsushi Kaneda et al.
CANCER RESEARCH (2012)
Epstein-Barr virus-associated gastric carcinoma
Masashi Fukayama et al.
PATHOLOGY RESEARCH AND PRACTICE (2011)
Gastric Cancer: An Infectious Disease
M. Blanca Piazuelo et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2010)
RAF may induce cell proliferation through hypermethylation of tumor suppressor gene promoter in gastric epithelial cells
Xia Wang et al.
CANCER SCIENCE (2009)
Stimulus Duration and Response Time Independently Influence the Kinetics of Lytic Cycle Reactivation of Epstein-Barr Virus
Jill Countryman et al.
JOURNAL OF VIROLOGY (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells
S. H. Lee et al.
ONCOGENE (2009)
p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo
Manran Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Activation of the lytic program of the Epstein-Barr virus in Burkitt's lymphoma cells leads to a two steps downregulation of expression of the proapoptotic protein BimEL, one of which is EBV-late-gene expression dependent
Lassad Oussaief et al.
VIROLOGY (2009)
p21 in cancer: intricate networks and multiple activities
Tarek Abbas et al.
NATURE REVIEWS CANCER (2009)
Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors
Jill K. Countryman et al.
JOURNAL OF VIROLOGY (2008)
A gene signature-based approach identifies mTOR as a regulator of p73
Jennifer M. Rosenbluth et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C Agonists
Jianjiang Ye et al.
JOURNAL OF VIROLOGY (2007)
Zebularine reactivates silenced E-cadherin but unlike 5-Azacytidine does not induce switching from latent to lytic Epstein-Barr virus infection in Burkitt's lymphoma Akata cells
Sieta P. Rao et al.
MOLECULAR CANCER (2007)
Activation of DNA methyltransferase 1 by EBV LMP1 involves c-Jun NH2-terminal kinase signaling
Chia-Lung Tsai et al.
CANCER RESEARCH (2006)
CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus
Moon-Sung Chang et al.
CLINICAL CANCER RESEARCH (2006)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus
M Kusano et al.
CANCER (2006)
A naturally derived gastric cancer cell line shows latency I Epstein-Barr virus infection closely resembling EBV-associated gastric cancer
ST Oh et al.
VIROLOGY (2004)
Epstein-Barr virus infection of human natural killer cell lines and peripheral blood natural killer cells
Y Isobe et al.
CANCER RESEARCH (2004)
Tumor suppressor activity of RUNX3
SC Bae et al.
ONCOGENE (2004)
The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the down-regulation of E-cadherin gene expression via activation of DNA methyltransferases
CN Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Activators of the Epstein-Barr virus lytic program concomitantly induce apoptosis, but lytic gene expression protects from cell death
GJ Inman et al.
JOURNAL OF VIROLOGY (2001)
Share Paper
